Setting targets for universal access to HIV prevention, treatment and care for injecting drug users (IDUs): Towards consensus and improved guidance

International Journal of Drug Policy

Volumn 19, Issue SUPPL. 1, 2008, Pages 5-14

  Donoghoe, Martin C ^a   Verster, Annette ^a   Pervilhac, Cyril ^a   Williams, Paul ^b  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b United Nations Office on Drugs and Crime Austria   (Austria)

Author keywords

Coverage; HIV AIDS; Injection drug use; Targets

Indexed keywords

ANTIRETROVIRUS AGENT; BUPRENORPHINE; METHADONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; DRUG DEPENDENCE; EPIDEMIC; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTERNATIONAL COOPERATION; LEADERSHIP; MIXED INFECTION; OPIATE ADDICTION; PATIENT CARE; POLITICS; POPULATION SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUBSTANCE ABUSE; SYRINGE; UNITED NATIONS; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 41149086454     PISSN: 09553959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugpo.2007.12.002     Document Type: Note

References (71)

1. Academy for Educational Development (2000). A comprehensive approach is a more effective approach. In Centers for Disease Control and Prevention, A comprehensive approach: preventing blood-borne infections among injecting drug users (pp. 21-39). Atlanta GA: Centers for Disease Control and Prevention.
2. Aceijas C., Stimson G.V., Hickman M., and Rhodes T. Global overview of injecting drug use and HIV infection and injecting drug users. AIDS 18 (2004) 2295-2303
3. Aceijas C., Friedman S.R., Cooper H., Stimson G.V., and Hickman M. Estimates of injecting drug users at national and local level in developing and transitional countries and gender and age distribution. Sexually Transmitted Infections 82 (2006) 10-17
4. Aceijas C., Oppenheimer E., Stimson G.V., Ashcroft R.E., Matic S., and Hickman M. Antiretroviral treatment for injecting drug users in developing and transitional countries: One year before the end of 3 by 5. Addiction 101 (2006) 1246-1253
5. Aggleton P., Jenkins P., and Malcolm A. HIV/AIDS and injecting drug use: Information, education and communication. International Journal of Drug Policy 16 1 (2005) S21-S30
6. Alliance for Open Society International (2007). Unique Identifier Code DDRP Best Practice Collection. Retrieved October 11, 2007 from http://www.ddrprogram.org/323.
7. Baker A., Lee N.K., Claire M., Lewin T.J., Grant T., Pohlman S., et al. Brief cognitive behavioural interventions for regular amphetamine users: A step in the right direction. Addiction 100 3 (2005) 367-378
8. Ball A.L. HIV, injecting drug use and harm reduction: A public health response. Addiction 102 (2007) 684-690
9. Ball A., Weiler G., Beg M., and Doupe A. Editorial. Supplement World Health Organization evidence for action for HIV prevention, treatment and care among injecting drug users. International Journal of Drug Policy 16 1 (2005) S1-S6
10. Bluthenthal R.N., Anderson R., Flynn N.M., and Krall A.H. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug and Alcohol Dependence 89 (2007) 214-222
11. Bluthenthal R.N., Ridgeway G., Schell T., Anderson R., Flynn N.M., and Kral A.H. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction 102 (2007) 638-646
12. Bollerup A.R., Donoghoe M.C., Lazarus J.V., and Matic S. Access to HAART for injecting drug users in the WHO European region 2002-2005. Eighteenth international conference on the reduction of drug related harm Warsaw Poland (2007) [Abstract 930]
13. Brown T., and Peerapatanapokin W. The Asian epidemic model: A process model for exploring HIV policy and programme alternatives in Asia. Sexually Transmitted Infections 80 i (2004) 19
14. Centers for Disease Control and Prevention. New attitudes and strategies: A comprehensive approach to preventing blood-borne infections among IDUs (2000), Centers for Disease Control and Prevention, Atlanta, GA
15. Coyle S.L., Needle R.H., and Normand J. Outreach-based HIV prevention for injecting drug users: A review of published outcome data. Public Health Reports 113 Suppl. 1 (1998) 19-30
16. Des Jarlais D.C., and Friedman S. Fifteen years of preventing HIV infection among injecting drug users: What we have learned, what we have not learned, what we have done, what we have not done. Public Health Reports 113 Suppl. 1 (1998) 182-188
17. Des Jarlais D.C., and Semaan S. Interventions to reduce the sexual risk behaviour of injecting drug users. International Journal of Drug Policy 16 1 (2005) S58-S66
18. Des Jarlais D.C., Friedman P., Hagen H., Friedman S.R., and World Health Organization Multi-Centre Study of AIDS and Injecting Drug Use. The protective effect of AIDS-related behavioural change among injection drug users: A cross-national study. American Journal of Public Health 86 12 (1996) 1780-1785
19. Donoghoe M.C. Sex, HIV and the injecting drug users. British Journal of Addiction 87 (1992) 405-416
20. Donoghoe M.C. Injecting drug use, harm reduction and HIV/AIDS. In: Matic S., Lazarus J.V., and Donoghoe M.C. (Eds). HIV/AIDS in Europe: Moving from death sentence to chronic disease management (2006), WHO Regional Office for Europe, Copenhagen 43-66
21. Donoghoe M.C., Lazarus J.V., and Matic S. HIV/AIDS in the transitional countries of eastern Europe and central Asia. Clinical Medicine 5 (2005) 487-490
22. Donoghoe M.C., Bollerup A.R., Lazarus J.V., Nielsen S., and Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the World Health Organization European Region 2002-2004. International Journal of Drug Policy 18 (2007) 271-280
23. Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia (2004). Retrieved November, 23, 2007 from http://www.euro.who.int/eprise/main/WHO/Progs/SHA/treatment/20051018_1.
24. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2004). Recommended draft technical tools and guidelines. Key epidemiological indicator: Prevalence of problem drug use. Retrieved November 26, 2007 from http://www.emcdda.europa.eu/?nnodeid=1372.
25. Farrell M., Gowing L., Marsden J., Ling W., and Ali R. Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy 16 1 (2005) S67-S75
26. Fischer B., Turnbull S., Poland B., and Haydon E. Drug use, risk and urban order: Examining supervised injection sites (SISs) as governmentality. International Journal of Drug Policy 15 (2004) 357-365
27. Friedman S.R., Templaski B., Cooper H., Perlis T., Keem M., Friedman R., et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degree of service provision for injecting drug users. Journal of Urban Health: Bulletin of the New York Academy of Medicine 81 3 (2004) 377-400
28. The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) (2006). Investing in impact: Mid-year results report 2006. Geneva: The Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). Retrieved November 26, 2007 from: http://www.theglobalfund.org/en/files/about/replenishment/progress_repor t_midyear_2006.pdf.
29. Hickman M., Taylor C., Chatterjee A., Degenhardt L., Frischer M., Hay G., et al. Estimating the prevalence of problematic drug use: A review of methods and their application. UN Bulletin on Narcotics 54 (2002) 15-32
30. Hickman M., Higgins V., Hope V., Bellis M., Tilling K., Walker A., et al. Injecting drug use in Brighton, Liverpool, and London: Best estimates of prevalence and coverage of public health indicators. Journal of Epidemiology and Community Health 58 (2004) 766-771
31. Institute of Medicine of the National Academies. Preventing HIV infection among injecting drug users in high risk countries: An assessment of the evidence (2006), The National Academic Press, Washington, DC
32. International Treatment Preparedness Coalition (ITPC) (2007). Missing the Target #4. Retrieved November 26, 2007 from: http://www.icaso.org/resources/itpc_missing_the_target_4.pdf.
33. Lert F., and Kazatchkine M. Anti-retroviral treatment and care for injecting drug users: An evidence-based overview. International Journal of Drug Policy 18 4 (2007) 255-261
34. Long E.F., Brandeau M.L., Galvin C.M., Vinichenko T., Tole S.P., Schwartz A., et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 20 (2006) 2207-2214
35. Metzger D.S., Woody G.E., McLellan A.T., and O'Brien C.P. Human immunodeficiency virus seroconversion among intravenous drug users in- and out of treatment: An 18-month prospective follow-up. JAIDS 6 (1993) 1049-1059
36. Moatti J.P., Carrieri M.P., Spire B., Gastaut J.A., Cassuto J.P., Moreau J., and The Manif 2000 Study Group. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. AIDS 14 (2000) 151-155
37. Needle R.H., Burrows D., Friedman S.R., Dorabjee J., Touze G., Badrieva L., et al. Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users. International Journal of Drug Policy 16 1 (2005) S45-S57
38. Rawson R.A., McCann M.J., Flammino F., Shoptaw S., Miotto K., Reiber C., et al. A comparison of contingency management and cognitive-behavioural approaches for stimulant-dependent individuals. Addiction 101 2 (2006) 267-274
39. Sarang A., Stuikyte R., and Bykov R. Implementation of harm reduction in central and eastern Europe and central Asia. International Journal of Drug Policy 18 2 (2007) 129-135
40. Sarang A., Rhodes T., and Platt L. Access to syringes in three Russian cities: Implications for syringe distribution and coverage. International Journal of Drug Policy 19S (2008) S25-S36
41. Sepúlveda J. PEPFAR implementation. Progress and promise (2007), Institute of Medicine. The National Academies Press, Washington, DC
42. Sharma M., Burrows D., and Bluthenthal R. Coverage of HIV prevention for injection drug users: Confusions, aspirations, definitions and ways forward. International Journal of Drug Policy 18 (2007) 92-98
43. Spire B., Lucas G.M., and Carrieri P. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). International Journal of Drug Policy 18 (2007) 262-270
44. Joint United Nations Programme on HIV/AIDS (UNAIDS). Considerations for countries to set their own national targets for aids prevention, treatment and care (2006), Joint United Nations Programme UNAIDS, Geneva
45. Joint United Nations Programme on HIV/AIDS (UNAIDS). Operational guidance on setting national targets for moving towards universal access, Section 4. Setting ambitious targets (2006), Joint United Nations Programme UNAIDS, Geneva (pp.13-18)
46. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS action plan on intensifying HIV prevention (2006), Joint United Nations Programme UNAIDS, Geneva
47. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2006d). Report on the global AIDS epidemic: A UNAIDS 10th anniversary special edition. Geneva: Joint United Nations Programme UNAIDS.
48. Joint United Nations Programme on HIV/AIDS (UNAIDS). High coverage sites HIV prevention among injecting drug users in transitional and developing countries: Case studies (2006), Joint United Nations Programme UNAIDS, Geneva
49. Joint United Nations Programme on HIV/AIDS (UNAIDS). A framework for monitoring and evaluating HIV prevention programmes for most-at-risk populations (2007), Joint United Nations Programme UNAIDS, Geneva
50. United Nations (2001). Declaration of Commitment on HIV/AIDS-United Nations special session on HIV/AIDS. Resolution A/RES/S-26/2 adopted by the UN General Assembly twenty-sixth special session, June 25-27, 2001. New York: United Nations. Retrieved November 23, 2007 from: http://www.un.org/ga/aids/docs/aress262.pdf.
51. United Nations (2006a). Towards universal access: Assessment by the Joint United Nations Programme on HIV/AIDS on scaling up HIV prevention, treatment, care and support UN. Document A/60/737 submitted to UN General Assembly. Retrieved November 23, 2007 from: http://data.unaids.org/pub/InformationNote/2006/20060324_hlm_ga_a60737_e n.pdf.
52. United Nations (2006b). Political Declaration on HIV/AIDS. Resolution 60/262, adopted at United Nations General Assembly, Sixtieth Session, June 2006. New York: United Nations.
53. United Nations Office on Drugs Crime (UNODC). Estimating prevalence: Indirect methods for estimating the size of the drug problem (2003), UNODC, Vienna
54. Verster A.D., and Buning E. Methadone guidelines (2000), EuroMethwork, Amsterdam
55. Vickerman P., Hickman M., Rhodes T., and Watts C. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. JAIDS 42 3 (2006) 355-361
56. World Health Organization (WHO). Global health-Sector strategy for HIV/AIDS 2003-2007 (2003), World Health Organization, Geneva
57. World Health Organization (WHO). Evidence for action technical paper. Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users (2004), World Health Organization, Geneva
58. World Health Organization (WHO). Evidence for action technical paper. Effectiveness of drug dependence treatment in preventing HIV among injecting drug users (2004), World Health Organization, Geneva
59. World Health Organization (WHO). Evidence for action technical paper. Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users (2004), World Health Organization, Geneva
60. World Health Organization (WHO) (2005). Health and the millennium development goals. Geneva: World Health Organization. Retrieved November 23, 2007 from: http://www.who.int/hdp/publications/mdg_en.pdf.
61. World Health Organization (WHO). HIV/AIDS programme towards universal access by 2010. How WHO is working with countries to scale-up HIV prevention, treatment, care and support (2006), World Health Organization, Geneva
62. World Health Organization (WHO), and Joint United Nations Programme on HIV/AIDS (UNAIDS). Treating 3 million by 2005. Making it happen. The WHO Strategy (2003), World Health Organization, Geneva
63. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS), and United Nations Office on Drugs and Crime (UNODC). Advocacy guide: HIV/AIDS prevention among injecting drug users (2004), World Health Organization, Geneva
64. World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC), & Joint United Nations Programme on HIV/AIDS (UNAIDS) (2004). Evidence for action policy brief: HIV/AIDS and injecting drug use reduction of HIV transmission in prisons. (HIV/2004.02). Geneva: World Health Organization.
65. World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC), & Joint United Nations Programme on HIV/AIDS (UNAIDS) (2007). Evidence for action technical paper. Comprehensive review of effectiveness of interventions addressing HIV in prisons. Geneva: World Health Organization.
66. World Health Organization Regional Office for Europe. Status paper on prisons, drugs and harm reduction (2005), World Health Organization Regional Office for Europe, Copenhagen
67. World Health Organization Regional Office for Europe (2006a). Clinical protocol on HIV/AIDS treatment and care for injecting drug users. Copenhagen: World Health Organization Regional Office for Europe. Retrieved October 11, 2007 from: http://www.euro.who.int/aids/treatment/20060801_1.
68. World Health Organization Regional Office for Europe (2006b). HIV/AIDS protocols on treatment and care. Copenhagen: World Health Organization Europe. Retrieved October 11, 2007 from: http://www.euro.who.int/aids/treatment/20060801_1.
69. Wiessing, L.G., Denis, B., Guttormsson, U., Hass, S., Hamouda, O., Hariga, F., et al. (2001). Estimating coverage of harm reduction measures for injection drug users in the European Union. Proceedings of 2000 Global Research Network Meeting on HIV Prevention in Drug-Using Populations. Durban, South Africa, Third Annual Meeting, July 5-7, 2000, National Institute on Drug Abuse. National Institutes of Health-U.S. Department of Health and Human Services. Retrieved October 11, 2007 from: http://www.emcdda.europa.eu/?fuseaction=public.AttachmentDownload&nN o.
70. Wodak A., and Cooney A. Effectiveness of sterile needle and syringe programmes. International Journal of Drug Policy 16 1 (2005) S31-S44
71. Wodak A., and Cooney A. Do needle exchange programmes reduce HIV infection among injecting drug users: A comprehensive review of the international evidence. Substance Use Misuse 41 (2006) 777-813